Elicera Therapeutics AB (8E8) Ratios
Elicera Therapeutics AB Ratios
DE:8E8's free cash flow for Q2 2026 was $-3.95M. For the 2026 fiscal year, DE:8E8's free cash flow was increased by $4.00 and operating cash flow was $-3.95M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.75 | 4.06 | 2.19 | 3.39 | 21.68 |
| Quick Ratio | 6.75 | 4.06 | 2.19 | 3.27 | 21.68 |
| Cash Ratio | 6.12 | 3.89 | 2.13 | 3.24 | 20.96 |
| Solvency Ratio | -4.29 | -2.37 | -1.19 | -1.44 | -5.24 |
| Operating Cash Flow Ratio | -5.31 | -3.45 | -1.08 | -0.63 | -5.72 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 23.35M | $ 20.77M | $ 16.39M | $ 32.29M | $ 51.71M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.17 | 1.33 | 1.84 | 1.41 | 1.05 |
| Debt Service Coverage Ratio | -2208.81 | -318.30 | 0.00 | -150.20 | -12193.11 |
| Interest Coverage Ratio | -2278.11 | -319.47 | 0.00 | -149.71 | -12204.06 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Net Debt to EBITDA | 1.43 | 1.57 | 1.72 | 2.26 | 4.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 100.00% | 99.89% | 100.01% | -1906.13% |
| EBIT Margin | 0.00% | -236.87% | -152.24% | -1518.67% | -2234986.20% |
| EBITDA Margin | 0.00% | -236.00% | -152.14% | -1517.73% | -2232980.07% |
| Operating Profit Margin | 0.00% | -236.87% | -252.24% | -1512.73% | -2234986.03% |
| Pretax Profit Margin | 0.00% | -226.01% | -146.02% | -1518.67% | -2235169.17% |
| Net Profit Margin | 0.00% | -226.01% | -146.02% | -1524.61% | -2235169.17% |
| Continuous Operations Profit Margin | 0.00% | -226.01% | -146.02% | -1518.67% | -2235169.17% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.39% | 100.00% |
| EBT Per EBIT | 97.00% | 95.42% | 57.89% | 100.39% | 100.01% |
| Return on Assets (ROA) | -63.48% | -58.45% | -54.33% | -42.14% | -23.97% |
| Return on Equity (ROE) | -74.51% | -77.56% | -99.98% | -59.50% | -25.12% |
| Return on Capital Employed (ROCE) | -76.81% | -81.29% | -172.71% | -59.03% | -25.11% |
| Return on Invested Capital (ROIC) | -76.81% | -81.29% | -172.71% | -59.03% | -25.12% |
| Return on Tangible Assets | -63.48% | -58.45% | -54.36% | -42.16% | -23.98% |
| Earnings Yield | -7.32% | -30.56% | -17.16% | -28.07% | -16.40% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 8.08 | 33.29 | 3.87 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.26 | 0.37 | 0.03 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.38 | 0.46 | 0.03 | 0.00 |
| Cash Conversion Cycle | 0.00 | 45.16 | 10.96 | 28468.55 | 63579.56 |
| Days of Sales Outstanding | 0.00 | 45.16 | 10.96 | 94.26 | 127062.28 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 51060.73 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 22686.44 | 63482.72 |
| Operating Cycle | 0.00 | 45.16 | 10.96 | 51154.99 | 127062.28 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.47 | -0.74 | -0.75 | -0.43 | -0.90 |
| Free Cash Flow Per Share | -0.47 | -0.74 | -0.75 | -0.43 | -0.90 |
| Dividend Paid and CapEx Coverage Ratio | -5387804.00 | 0.00 | -14922.51 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -5387804.00 | 0.00 | -14922.51 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | -3.29 | -1.33 | -6.70 | -24349.41 |
| Free Cash Flow Yield | -9.06% | -44.50% | -15.62% | -12.33% | -17.86% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.74 | -3.27 | -5.83 | -3.56 | -6.10 |
| Price-to-Sales (P/S) Ratio | 0.00 | 7.40 | 8.51 | 54.32 | 136308.38 |
| Price-to-Book (P/B) Ratio | 10.19 | 2.54 | 5.83 | 2.12 | 1.53 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.04 | -2.25 | -6.40 | -8.11 | -5.60 |
| Price-to-Operating Cash Flow Ratio | -11.04 | -2.25 | -6.40 | -8.11 | -5.60 |
| Price-to-Earnings Growth (PEG) Ratio | 0.54 | 0.08 | 0.38 | -0.18 | -0.01 |
| Enterprise Value Multiple | -12.25 | -1.56 | -3.87 | -1.32 | -2.11 |
| Enterprise Value | 213.10M | 26.32M | 66.16M | 25.71M | 27.62M |
| EV to EBITDA | -12.25 | -1.56 | -3.87 | -1.32 | -2.11 |
| EV to Sales | 0.00 | 3.69 | 5.89 | 20.09 | 47052.63 |
| EV to Free Cash Flow | -9.89 | -1.12 | -4.43 | -3.00 | -1.93 |
| EV to Operating Cash Flow | -9.89 | -1.12 | -4.43 | -3.00 | -1.93 |
| Tangible Book Value Per Share | 0.51 | 0.66 | 0.83 | 1.66 | 3.28 |
| Shareholders’ Equity Per Share | 0.51 | 0.66 | 0.83 | 1.66 | 3.28 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.23 | 0.57 | 0.06 | 0.00 |
| Net Income Per Share | -0.38 | -0.51 | -0.83 | -0.99 | -0.82 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.95 | 0.96 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 3.36 | 0.00 | 0.00 | 15258.62 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.20 | 1.42 | 0.91 | 0.44 | 1.09 |
Currency in SEK
